{"gene":"PRIMA1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2002,"finding":"PRiMA (proline-rich membrane anchor, encoded by PRIMA1) is the membrane anchor of acetylcholinesterase (AChE) in mammalian brain and muscle cell membranes. PRiMA organizes AChE into tetramers and anchors them at the cell surface of transfected cells; endogenous AChE in neural cell membranes is anchored through its interaction with PRiMA.","method":"Molecular cloning, transfection of COS cells, biochemical fractionation, and demonstration of AChE tetramer formation at the cell surface","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — cloning plus reconstitution in transfected cells plus demonstration in native neural membranes, foundational study replicated extensively by subsequent work","pmids":["11804574"],"is_preprint":false},{"year":2003,"finding":"PRiMA is expressed predominantly in cholinergic neurons in the mouse brain, and its expression level is a limiting factor for production of the AChET–PRiMA complex (the major AChE component in brain). PRiMA exists as two alternative splice variants (PRiMA I and PRiMA II) differing in their cytoplasmic regions in both mouse and human.","method":"In situ hybridization, cholinesterase activity assays of molecular forms across brain structures, RT-PCR characterization of splice variants","journal":"The European journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ISH, activity assays, RT-PCR) in native tissue, consistent with cloning paper","pmids":["14622217"],"is_preprint":false},{"year":2006,"finding":"The proline-rich extracellular motif of PRiMA (specifically the peptidic motif RP4LP10RL) is sufficient to induce assembly of a hetero-oligomeric complex with four AChET subunits and their secretion. Short PRiMA mutants truncated within the proline-rich motif cause intracellular degradation of associated AChE subunits rather than tetramer formation.","method":"Deletion and point-mutation analysis of PRiMA expressed in transfected COS cells, measurement of secreted and membrane-bound AChE activity","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis with functional reconstitution in transfected cells, multiple mutants tested","pmids":["17158452"],"is_preprint":false},{"year":2008,"finding":"PRiMA associates differently with AChE than ColQ does: in complexes formed with the PRAD of PRiMA, light (non-disulfide-linked) AChE dimers predominate, whereas heavy (disulfide-linked) dimers are rare, in contrast to ColQ-linked complexes. PRiMA has four cysteines upstream of its PRAD that can disulfide-bond all four AChE subunits.","method":"Transfection of COS cells with PRiMA/ColQ chimeras and cysteine mutants, SDS-PAGE under reducing/non-reducing conditions, analysis of native brain AChE complexes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis and chimera analysis with biochemical readout, verified in brain tissue","pmids":["18511416"],"is_preprint":false},{"year":2009,"finding":"PRiMA expression in cortical neurons is transcriptionally upregulated during neuronal differentiation via a MAP kinase (Raf/MEK/ERK)-dependent signaling pathway. Inhibition of MEK with U0126 blocks both PRiMA transcript induction and PRiMA promoter-driven luciferase activity. Overexpression of activated Raf induces both PRiMA and AChET transcripts.","method":"RT-PCR, promoter-luciferase reporter assays in cortical neurons, pharmacological MEK inhibition (U0126), overexpression of active Raf mutant","journal":"Brain research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assay, pharmacological inhibition, gain-of-function) in primary neurons","pmids":["19368807"],"is_preprint":false},{"year":2009,"finding":"PRiMA-linked G4 AChE is present at vertebrate neuromuscular junctions (NMJs) and is contributed by both motor neurons (spinal cord) and muscle. After denervation, expression of PRiMA, AChET, and G4 AChE decreases markedly in spinal cord and in fast- and slow-twitch muscles, indicating motor neuron–dependent regulation of this complex at the NMJ.","method":"Western blot, ELISA, immunohistochemistry in developing rat muscle and spinal cord, denervation experiments","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — denervation experiment directly links motor neuron to PRiMA/G4 AChE expression, corroborated by developmental time-course","pmids":["19490106"],"is_preprint":false},{"year":2010,"finding":"PRiMA-linked AChE tetramers are localized in membrane lipid rafts of neuronal cells, and this raft association depends on a cholesterol recognition/interaction amino acid consensus (CRAC) motif at the junction of the transmembrane and cytoplasmic domains of PRiMA. The longer PRiMA I isoform confers stronger raft association than PRiMA II, implicating the cytoplasmic domain in stabilizing raft localization.","method":"Cold Triton X-100 extraction/sucrose gradient fractionation of rat brain and transfected NG108-15 cells, CRAC motif mutation analysis, developmental fractionation time-course","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — raft fractionation in native brain tissue and transfected cells, CRAC motif identified by mutagenesis, isoform comparison","pmids":["20147288"],"is_preprint":false},{"year":2010,"finding":"PRiMA-linked AChE tetramers assemble from AChET and BChET homodimers (not heterodimers); dimer formation depends on catalytic domains and tetramer assembly requires the C-terminal t-peptides of cholinesterase subunits. Hybrid AChE–BChE PRiMA-linked tetramers occur naturally in chicken brain and increase during development.","method":"Co-transfection with AChET/BChET mutants and PRiMA in cultured cells, non-reducing SDS-PAGE, sucrose gradient sedimentation, Western blot of chicken brain","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — systematic mutagenesis establishes assembly rules, verified in native tissue","pmids":["20566626"],"is_preprint":false},{"year":2011,"finding":"N-linked glycosylation of AChET is required for full enzymatic activity of PRiMA-linked AChE tetramers but is not required for oligomerization. Glycan-depleted PRiMA-linked G4 AChE tetramers assemble in the endoplasmic reticulum but are not transported to the Golgi or plasma membrane.","method":"Site-directed mutagenesis of all N-glycosylation sites in AChET expressed with PRiMA in HEK293T cells, kinetic analysis (Km), subcellular fractionation, immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with glycosylation-null mutant, multiple functional and trafficking readouts","pmids":["21795704"],"is_preprint":false},{"year":2014,"finding":"Presenilin-1 (PS1)/γ-secretase cleaves PRiMA, generating a C-terminal PRiMA fragment that is detectable in the nucleus. Inhibition of γ-secretase increases the level of PRiMA-linked AChE at the cell surface. The proportion of raft-residing AChE–PRiMA is altered in a PS1 conditional knockout mouse.","method":"γ-secretase inhibitor (DAPT) treatment of CHO cells overexpressing PRiMA and AChE, immunofluorescence detection of C-terminal PRiMA fragment, analysis of PS1 conditional KO mouse raft fractions","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition plus KO mouse, single lab, cleavage fragment identified but full characterization limited","pmids":["24612677"],"is_preprint":false},{"year":2008,"finding":"cAMP-dependent signaling (stimulated by dibutyryl-cAMP and forskolin) upregulates both AChET and PRiMA I mRNA expression in PC12 cells and increases G1 and G4 AChE isoforms, indicating that PRiMA-linked G4 AChE assembly is regulated by a cAMP-dependent pathway.","method":"Pharmacological treatment of PC12 cells with Bt2-cAMP/forskolin, RT-PCR, AChE activity measurement, sucrose density gradient sedimentation","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical readouts in a cell culture model, single lab","pmids":["18514641"],"is_preprint":false},{"year":2015,"finding":"A homozygous splice-site mutation (c.93+2T>C) in PRIMA1 causes skipping of the first coding exon (demonstrated by minigene assay), effectively creating a PRIMA1 knockout, and segregates with autosomal recessive nocturnal frontal lobe epilepsy and intellectual disability in a human family. Consistent with PRiMA knockout mouse data showing AChE reduction and acetylcholine accumulation, loss of PRIMA1 leads to enhanced cholinergic tone as the likely disease mechanism.","method":"Whole-exome sequencing, linkage analysis, minigene splicing assay to demonstrate exon skipping, reference to PRiMA KO mouse phenotype","journal":"Annals of clinical and translational neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene functional validation of splice defect plus human genetics; disease mechanism inferred from KO mouse data","pmids":["26339676"],"is_preprint":false},{"year":2015,"finding":"In PRiMA knockout mice, which develop severely reduced AChE activity and chronically elevated extracellular acetylcholine, muscarinic M2 autoreceptors are dysfunctional and fail to reduce ACh release in vivo, likely due to receptor downregulation and/or loss of receptor-effector coupling caused by chronic high ACh.","method":"PRiMA KO mouse model, in vivo microdialysis of striatal and hippocampal ACh, pharmacological challenge with oxotremorine (M2 agonist) and scopolamine (antagonist)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with in vivo functional assay, single lab","pmids":["26506622"],"is_preprint":false},{"year":2009,"finding":"A second splice variant of PRiMA (PRiMA II) with a distinct 26-amino-acid cytoplasmic C-terminus exists in chicken. Both chicken PRiMA I and PRiMA II can organize G4 AChE formation when co-expressed with AChET in cultured cells. PRiMA I expression is higher in slow-twitch than fast-twitch chicken muscle, suggesting fiber-type-specific regulation of G4 AChE.","method":"RT-PCR, bioinformatic analysis, co-expression in cultured cells, fiber-type specific expression analysis","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution in cells confirmed, expression pattern data from single lab","pmids":["19539694"],"is_preprint":false}],"current_model":"PRIMA1 encodes PRiMA (proline-rich membrane anchor), a single-pass transmembrane protein that organizes acetylcholinesterase (AChE) catalytic subunits into tetramers and anchors them in plasma membrane lipid rafts of neurons and muscle cells via a proline-rich extracellular domain that binds the t-peptide of AChET; raft targeting requires a CRAC cholesterol-binding motif in PRiMA's transmembrane-cytoplasmic junction, glycosylation of AChET is needed for enzymatic activity but not assembly, γ-secretase/presenilin-1 cleaves PRiMA releasing a nuclear C-terminal fragment, PRiMA expression is transcriptionally induced during neuronal differentiation via a Raf/MEK/ERK MAP kinase pathway and by cAMP signaling, and loss-of-function mutations in PRIMA1 cause accumulation of synaptic acetylcholine leading to nocturnal frontal lobe epilepsy in humans."},"narrative":{"mechanistic_narrative":"PRIMA1 encodes PRiMA (proline-rich membrane anchor), the dedicated transmembrane scaffold that organizes acetylcholinesterase (AChE) catalytic subunits into G4 tetramers and anchors them at the cell surface of brain and muscle membranes [PMID:11804574]. Assembly is driven by PRiMA's proline-rich extracellular motif (PRAD), which is sufficient to nucleate a hetero-oligomer of four cholinesterase T-subunits and direct their secretion or membrane retention; truncation within this motif instead diverts associated subunits to intracellular degradation [PMID:17158452], and tetramer formation depends on the C-terminal t-peptides of the cholinesterase subunits [PMID:20566626]. PRiMA-linked tetramers are targeted to membrane lipid rafts through a CRAC cholesterol-recognition motif at the transmembrane–cytoplasmic junction, with the longer PRiMA I isoform conferring stronger raft association [PMID:20147288], while N-glycosylation of the AChE subunit is required for full catalytic activity and for trafficking beyond the endoplasmic reticulum but is dispensable for oligomerization [PMID:21795704]. PRiMA is expressed predominantly in cholinergic neurons and is the limiting factor for assembly of the major brain AChE form [PMID:14622217]; its transcription is induced during neuronal differentiation through a Raf/MEK/ERK pathway [PMID:19368807] and by cAMP signaling [PMID:18514641], and the complex is regulated at the neuromuscular junction in a motor-neuron-dependent manner [PMID:19490106]. The complex is further controlled post-translationally by presenilin-1/γ-secretase, which cleaves PRiMA to release a nuclear-localized C-terminal fragment and modulates the surface pool of AChE [PMID:24612677]. Loss-of-function mutation of PRIMA1 causes autosomal recessive nocturnal frontal lobe epilepsy with intellectual disability, with accumulation of synaptic acetylcholine and elevated cholinergic tone as the disease mechanism [PMID:26339676].","teleology":[{"year":2002,"claim":"Established the molecular identity of the long-sought membrane anchor for brain and muscle AChE, answering how soluble catalytic subunits become surface-tethered tetramers.","evidence":"Molecular cloning and reconstitution in transfected COS cells, with confirmation in native neural membranes","pmids":["11804574"],"confidence":"High","gaps":["Structure of the PRiMA–AChE complex not resolved","Stoichiometric and kinetic details of assembly not defined at the time"]},{"year":2003,"claim":"Defined the cellular distribution and rate-limiting role of PRiMA, showing its expression in cholinergic neurons controls how much of the major brain AChE form is produced, and revealed splice variant diversity.","evidence":"In situ hybridization, cholinesterase activity assays of molecular forms, and RT-PCR of splice variants in mouse and human tissue","pmids":["14622217"],"confidence":"High","gaps":["Functional distinction between PRiMA I and II not established here","Mechanism limiting complex production not detailed"]},{"year":2006,"claim":"Mapped the assembly determinant to the proline-rich PRAD motif and showed it is both sufficient for tetramer formation and required to prevent degradation of unassembled subunits.","evidence":"Deletion and point mutagenesis of PRiMA in transfected COS cells with secreted/membrane AChE activity readouts","pmids":["17158452"],"confidence":"High","gaps":["Atomic details of PRAD–t-peptide interaction not resolved","Quality-control machinery degrading mis-assembled subunits not identified"]},{"year":2008,"claim":"Distinguished PRiMA-based assembly from ColQ-based assembly and identified the cysteines that disulfide-link the tetramer, clarifying complex architecture.","evidence":"PRiMA/ColQ chimeras and cysteine mutants in COS cells, reducing/non-reducing SDS-PAGE, native brain analysis","pmids":["18511416"],"confidence":"High","gaps":["Functional consequence of light- vs heavy-dimer predominance unknown","No structural model of the disulfide network"]},{"year":2008,"claim":"Identified a regulatory input controlling assembly, showing cAMP signaling coordinately upregulates PRiMA and AChE to increase G4 levels.","evidence":"Bt2-cAMP/forskolin treatment of PC12 cells with RT-PCR, activity assays, and sucrose gradients","pmids":["18514641"],"confidence":"Medium","gaps":["Transcription factors mediating cAMP induction not identified","Single cell-line model"]},{"year":2009,"claim":"Showed PRiMA transcription is developmentally induced through Raf/MEK/ERK signaling, linking neuronal differentiation cues to cholinergic enzyme assembly.","evidence":"Promoter-luciferase reporters, MEK inhibition (U0126), and active-Raf overexpression in cortical neurons","pmids":["19368807"],"confidence":"High","gaps":["Direct promoter-binding transcription factors not defined","Crosstalk with cAMP pathway not resolved"]},{"year":2009,"claim":"Demonstrated motor-neuron-dependent regulation of PRiMA-linked G4 AChE at the neuromuscular junction.","evidence":"Western blot, ELISA, immunohistochemistry, and denervation in rat muscle and spinal cord","pmids":["19490106"],"confidence":"High","gaps":["Neuronal signals driving muscle PRiMA expression not identified","Relative contributions of nerve vs muscle pools not quantified"]},{"year":2009,"claim":"Characterized the PRiMA II splice variant and showed both isoforms support G4 assembly, with isoform expression tracking muscle fiber type.","evidence":"RT-PCR, bioinformatics, co-expression in cultured cells, and fiber-type analysis in chicken","pmids":["19539694"],"confidence":"Medium","gaps":["Functional advantage of isoform-specific cytoplasmic tails unclear","Data from chicken; mammalian relevance partial"]},{"year":2010,"claim":"Defined the lipid-raft targeting mechanism, localizing PRiMA-linked tetramers to rafts via a CRAC cholesterol-binding motif and the cytoplasmic domain.","evidence":"Detergent-resistant membrane fractionation of brain and NG108-15 cells with CRAC motif mutagenesis and isoform comparison","pmids":["20147288"],"confidence":"High","gaps":["Functional role of raft residence for cholinergic signaling not established","Direct cholesterol binding not biophysically measured"]},{"year":2010,"claim":"Established subunit assembly rules, showing tetramers build from cholinesterase homodimers via catalytic domains and t-peptides, and that natural AChE–BChE hybrids form.","evidence":"Co-transfection of AChET/BChET mutants with PRiMA, non-reducing SDS-PAGE, sedimentation, and chicken brain analysis","pmids":["20566626"],"confidence":"High","gaps":["Physiological role of hybrid tetramers unknown","Determinants of homo- vs heterodimer preference not fully defined"]},{"year":2011,"claim":"Separated the requirements for catalytic activity and assembly/trafficking, showing AChE N-glycosylation is needed for activity and ER exit but not for oligomerization.","evidence":"Glycosylation-null AChET mutants co-expressed with PRiMA in HEK293T cells with kinetic, fractionation, and immunofluorescence readouts","pmids":["21795704"],"confidence":"High","gaps":["Glycan-dependent ER export checkpoint not mechanistically identified","Whether PRiMA itself is glycosylation-dependent not addressed"]},{"year":2014,"claim":"Identified post-translational proteolytic regulation, showing γ-secretase/PS1 cleaves PRiMA to release a nuclear C-terminal fragment and controls the surface AChE pool.","evidence":"DAPT treatment of CHO cells, immunofluorescence of the C-terminal fragment, and PS1 conditional KO raft analysis","pmids":["24612677"],"confidence":"Medium","gaps":["Function of the nuclear PRiMA fragment unknown","Cleavage site and physiological trigger not defined","Single-lab finding"]},{"year":2015,"claim":"Connected PRIMA1 loss of function to human disease, establishing it as a cause of autosomal recessive nocturnal frontal lobe epilepsy via cholinergic excess.","evidence":"Whole-exome sequencing, linkage, minigene splicing assay of a c.93+2T>C variant, referenced to KO mouse phenotype","pmids":["26339676"],"confidence":"Medium","gaps":["Disease mechanism inferred from mouse rather than patient tissue","Single family","Genotype-phenotype range not defined"]},{"year":2015,"claim":"Linked chronic loss of PRiMA-anchored AChE to downstream cholinergic circuit dysfunction, showing M2 autoreceptor failure in vivo.","evidence":"PRiMA KO mouse with striatal/hippocampal microdialysis and muscarinic pharmacological challenge","pmids":["26506622"],"confidence":"Medium","gaps":["Whether M2 dysfunction is cause or consequence of elevated ACh not separated","Receptor-level molecular changes not directly measured"]},{"year":null,"claim":"The function of the γ-secretase-generated nuclear PRiMA fragment and whether PRiMA has signaling roles independent of AChE anchoring remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No identified nuclear targets or transcriptional effects of the C-terminal fragment","No structural model of the PRiMA–AChE complex","AChE-independent functions of PRiMA untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,2,7]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,2]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[8]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9]}],"pathway":[],"complexes":["PRiMA-AChE G4 tetramer"],"partners":["ACHE","BCHE","PSEN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q86XR5","full_name":"Proline-rich membrane anchor 1","aliases":[],"length_aa":153,"mass_kda":16.7,"function":"Required to anchor acetylcholinesterase (ACHE) to the basal lamina of the neuromuscular junction and to the membrane of neuronal synapses in brain. Also able to organize ACHE into tetramers (By similarity)","subcellular_location":"Cell membrane; Cell junction; Synapse","url":"https://www.uniprot.org/uniprotkb/Q86XR5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRIMA1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRIMA1","total_profiled":1310},"omim":[{"mim_id":"613851","title":"PROLINE-RICH MEMBRANE ANCHOR 1; PRIMA1","url":"https://www.omim.org/entry/613851"},{"mim_id":"100740","title":"ACETYLCHOLINESTERASE; ACHE","url":"https://www.omim.org/entry/100740"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":45.4},{"tissue":"intestine","ntpm":52.7}],"url":"https://www.proteinatlas.org/search/PRIMA1"},"hgnc":{"alias_symbol":["PRIMA"],"prev_symbol":[]},"alphafold":{"accession":"Q86XR5","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86XR5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86XR5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86XR5-F1-predicted_aligned_error_v6.png","plddt_mean":63.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRIMA1","jax_strain_url":"https://www.jax.org/strain/search?query=PRIMA1"},"sequence":{"accession":"Q86XR5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86XR5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86XR5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86XR5"}},"corpus_meta":[{"pmid":"19411067","id":"PMC_19411067","title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19411067","citation_count":493,"is_preprint":false},{"pmid":"15735745","id":"PMC_15735745","title":"PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15735745","citation_count":214,"is_preprint":false},{"pmid":"11804574","id":"PMC_11804574","title":"PRiMA: the membrane anchor of acetylcholinesterase in the brain.","date":"2002","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/11804574","citation_count":208,"is_preprint":false},{"pmid":"33946854","id":"PMC_33946854","title":"Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33946854","citation_count":183,"is_preprint":false},{"pmid":"21747087","id":"PMC_21747087","title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.","date":"2011","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21747087","citation_count":157,"is_preprint":false},{"pmid":"27298402","id":"PMC_27298402","title":"Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.","date":"2016","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27298402","citation_count":155,"is_preprint":false},{"pmid":"24157875","id":"PMC_24157875","title":"APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24157875","citation_count":148,"is_preprint":false},{"pmid":"12507923","id":"PMC_12507923","title":"Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.","date":"2002","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12507923","citation_count":144,"is_preprint":false},{"pmid":"25006124","id":"PMC_25006124","title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25006124","citation_count":137,"is_preprint":false},{"pmid":"21415220","id":"PMC_21415220","title":"PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21415220","citation_count":117,"is_preprint":false},{"pmid":"31488557","id":"PMC_31488557","title":"Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.","date":"2019","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31488557","citation_count":116,"is_preprint":false},{"pmid":"29258181","id":"PMC_29258181","title":"PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/29258181","citation_count":104,"is_preprint":false},{"pmid":"28753106","id":"PMC_28753106","title":"Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples.","date":"2017","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28753106","citation_count":96,"is_preprint":false},{"pmid":"18854743","id":"PMC_18854743","title":"Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications.","date":"2008","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/18854743","citation_count":90,"is_preprint":false},{"pmid":"19946333","id":"PMC_19946333","title":"Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19946333","citation_count":85,"is_preprint":false},{"pmid":"24030633","id":"PMC_24030633","title":"PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24030633","citation_count":79,"is_preprint":false},{"pmid":"30602570","id":"PMC_30602570","title":"p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30602570","citation_count":77,"is_preprint":false},{"pmid":"22411358","id":"PMC_22411358","title":"Mesotoga prima gen. nov., sp. nov., the first described mesophilic species of the Thermotogales.","date":"2012","source":"Extremophiles : life under extreme conditions","url":"https://pubmed.ncbi.nlm.nih.gov/22411358","citation_count":73,"is_preprint":false},{"pmid":"19787255","id":"PMC_19787255","title":"PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.","date":"2009","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19787255","citation_count":63,"is_preprint":false},{"pmid":"23355677","id":"PMC_23355677","title":"Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23355677","citation_count":62,"is_preprint":false},{"pmid":"25614142","id":"PMC_25614142","title":"Stimulation of suicidal erythrocyte death by PRIMA-1.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25614142","citation_count":61,"is_preprint":false},{"pmid":"24838627","id":"PMC_24838627","title":"PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.","date":"2014","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24838627","citation_count":55,"is_preprint":false},{"pmid":"15491287","id":"PMC_15491287","title":"Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/15491287","citation_count":55,"is_preprint":false},{"pmid":"26975633","id":"PMC_26975633","title":"APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26975633","citation_count":55,"is_preprint":false},{"pmid":"16168122","id":"PMC_16168122","title":"Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.","date":"2005","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/16168122","citation_count":53,"is_preprint":false},{"pmid":"20818419","id":"PMC_20818419","title":"PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20818419","citation_count":52,"is_preprint":false},{"pmid":"26482433","id":"PMC_26482433","title":"DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26482433","citation_count":51,"is_preprint":false},{"pmid":"26790143","id":"PMC_26790143","title":"p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.","date":"2016","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/26790143","citation_count":51,"is_preprint":false},{"pmid":"16398657","id":"PMC_16398657","title":"PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.","date":"2006","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16398657","citation_count":51,"is_preprint":false},{"pmid":"18663359","id":"PMC_18663359","title":"PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18663359","citation_count":50,"is_preprint":false},{"pmid":"15956247","id":"PMC_15956247","title":"Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.","date":"2005","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15956247","citation_count":49,"is_preprint":false},{"pmid":"25041721","id":"PMC_25041721","title":"Is the neutrophil a 'prima donna' in the procoagulant process during sepsis?","date":"2014","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25041721","citation_count":48,"is_preprint":false},{"pmid":"20147288","id":"PMC_20147288","title":"Targeting acetylcholinesterase to membrane rafts: a function mediated by the proline-rich membrane anchor (PRiMA) in neurons.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20147288","citation_count":48,"is_preprint":false},{"pmid":"21239882","id":"PMC_21239882","title":"PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21239882","citation_count":48,"is_preprint":false},{"pmid":"22885164","id":"PMC_22885164","title":"Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22885164","citation_count":46,"is_preprint":false},{"pmid":"26452133","id":"PMC_26452133","title":"PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26452133","citation_count":45,"is_preprint":false},{"pmid":"21795704","id":"PMC_21795704","title":"The assembly of proline-rich membrane anchor (PRiMA)-linked acetylcholinesterase enzyme: glycosylation is required for enzymatic activity but not for oligomerization.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21795704","citation_count":44,"is_preprint":false},{"pmid":"21647879","id":"PMC_21647879","title":"Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21647879","citation_count":43,"is_preprint":false},{"pmid":"14622217","id":"PMC_14622217","title":"Expression of PRiMA in the mouse brain: membrane anchoring and accumulation of 'tailed' acetylcholinesterase.","date":"2003","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/14622217","citation_count":37,"is_preprint":false},{"pmid":"24129240","id":"PMC_24129240","title":"Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24129240","citation_count":37,"is_preprint":false},{"pmid":"23355676","id":"PMC_23355676","title":"APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23355676","citation_count":37,"is_preprint":false},{"pmid":"33430525","id":"PMC_33430525","title":"Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33430525","citation_count":36,"is_preprint":false},{"pmid":"30772005","id":"PMC_30772005","title":"Adjuvant therapy of cytomegalovirus IgM + ve associated biliary atresia: Prima facie evidence of effect.","date":"2019","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/30772005","citation_count":36,"is_preprint":false},{"pmid":"27533246","id":"PMC_27533246","title":"Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27533246","citation_count":35,"is_preprint":false},{"pmid":"26986846","id":"PMC_26986846","title":"PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26986846","citation_count":33,"is_preprint":false},{"pmid":"22296923","id":"PMC_22296923","title":"Gene alterations at Drosophila inversion breakpoints provide prima facie evidence for natural selection as an explanation for rapid chromosomal evolution.","date":"2012","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22296923","citation_count":32,"is_preprint":false},{"pmid":"17113036","id":"PMC_17113036","title":"PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17113036","citation_count":31,"is_preprint":false},{"pmid":"26712693","id":"PMC_26712693","title":"Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26712693","citation_count":29,"is_preprint":false},{"pmid":"26771839","id":"PMC_26771839","title":"MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26771839","citation_count":28,"is_preprint":false},{"pmid":"18442053","id":"PMC_18442053","title":"PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18442053","citation_count":28,"is_preprint":false},{"pmid":"7410606","id":"PMC_7410606","title":"Naturally occurring alterations of cortical layers surrounding the fissura prima of rat cerebellum.","date":"1980","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/7410606","citation_count":28,"is_preprint":false},{"pmid":"26463477","id":"PMC_26463477","title":"PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26463477","citation_count":27,"is_preprint":false},{"pmid":"24512488","id":"PMC_24512488","title":"PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24512488","citation_count":27,"is_preprint":false},{"pmid":"19368807","id":"PMC_19368807","title":"Transcriptional regulation of proline-rich membrane anchor (PRiMA) of globular form acetylcholinesterase in neuron: an inductive effect of neuron differentiation.","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19368807","citation_count":27,"is_preprint":false},{"pmid":"18048389","id":"PMC_18048389","title":"In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18048389","citation_count":26,"is_preprint":false},{"pmid":"27533450","id":"PMC_27533450","title":"PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27533450","citation_count":26,"is_preprint":false},{"pmid":"22982566","id":"PMC_22982566","title":"Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22982566","citation_count":26,"is_preprint":false},{"pmid":"17158452","id":"PMC_17158452","title":"Assembly of acetylcholinesterase tetramers by peptidic motifs from the proline-rich membrane anchor, PRiMA: competition between degradation and secretion pathways of heteromeric complexes.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17158452","citation_count":26,"is_preprint":false},{"pmid":"23545415","id":"PMC_23545415","title":"PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23545415","citation_count":25,"is_preprint":false},{"pmid":"22189739","id":"PMC_22189739","title":"Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model.","date":"2011","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/22189739","citation_count":24,"is_preprint":false},{"pmid":"30755224","id":"PMC_30755224","title":"PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30755224","citation_count":23,"is_preprint":false},{"pmid":"16554962","id":"PMC_16554962","title":"Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-alpha on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells.","date":"2006","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/16554962","citation_count":23,"is_preprint":false},{"pmid":"19921694","id":"PMC_19921694","title":"MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19921694","citation_count":23,"is_preprint":false},{"pmid":"19490106","id":"PMC_19490106","title":"Restricted localization of proline-rich membrane anchor (PRiMA) of globular form acetylcholinesterase at the neuromuscular junctions--contribution and expression from motor neurons.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19490106","citation_count":23,"is_preprint":false},{"pmid":"25803193","id":"PMC_25803193","title":"PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.","date":"2015","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25803193","citation_count":22,"is_preprint":false},{"pmid":"29168598","id":"PMC_29168598","title":"PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/29168598","citation_count":21,"is_preprint":false},{"pmid":"20946886","id":"PMC_20946886","title":"PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20946886","citation_count":21,"is_preprint":false},{"pmid":"20178777","id":"PMC_20178777","title":"PRiMA directs a restricted localization of tetrameric AChE at synapses.","date":"2010","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/20178777","citation_count":21,"is_preprint":false},{"pmid":"26742039","id":"PMC_26742039","title":"Aberrant DNA Methylation of rDNA and PRIMA1 in Borderline Personality Disorder.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26742039","citation_count":20,"is_preprint":false},{"pmid":"31949132","id":"PMC_31949132","title":"Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1MET/APR-246.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31949132","citation_count":20,"is_preprint":false},{"pmid":"20566626","id":"PMC_20566626","title":"The PRiMA-linked cholinesterase tetramers are assembled from homodimers: hybrid molecules composed of acetylcholinesterase and butyrylcholinesterase dimers are up-regulated during development of chicken brain.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20566626","citation_count":20,"is_preprint":false},{"pmid":"26339676","id":"PMC_26339676","title":"PRIMA1 mutation: a new cause of nocturnal frontal lobe epilepsy.","date":"2015","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26339676","citation_count":19,"is_preprint":false},{"pmid":"23351152","id":"PMC_23351152","title":"PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.","date":"2013","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/23351152","citation_count":19,"is_preprint":false},{"pmid":"27806324","id":"PMC_27806324","title":"PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27806324","citation_count":18,"is_preprint":false},{"pmid":"16619536","id":"PMC_16619536","title":"Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16619536","citation_count":18,"is_preprint":false},{"pmid":"22798451","id":"PMC_22798451","title":"Genome sequence of the mesophilic Thermotogales bacterium Mesotoga prima MesG1.Ag.4.2 reveals the largest Thermotogales genome to date.","date":"2012","source":"Genome biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/22798451","citation_count":18,"is_preprint":false},{"pmid":"27056280","id":"PMC_27056280","title":"Autoantibodies to neuronal antigens in children with focal epilepsy and no prima facie signs of encephalitis.","date":"2016","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/27056280","citation_count":18,"is_preprint":false},{"pmid":"24027427","id":"PMC_24027427","title":"Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.","date":"2013","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24027427","citation_count":17,"is_preprint":false},{"pmid":"16970918","id":"PMC_16970918","title":"Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16970918","citation_count":16,"is_preprint":false},{"pmid":"14747684","id":"PMC_14747684","title":"Prima facie evidence that a phytocystatin for transgenic plant resistance to nematodes is not a toxic risk in the human diet.","date":"2004","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/14747684","citation_count":16,"is_preprint":false},{"pmid":"30895171","id":"PMC_30895171","title":"Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30895171","citation_count":15,"is_preprint":false},{"pmid":"29495002","id":"PMC_29495002","title":"Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29495002","citation_count":15,"is_preprint":false},{"pmid":"18511416","id":"PMC_18511416","title":"Acetylcholinesterase associates differently with its anchoring proteins ColQ and PRiMA.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18511416","citation_count":15,"is_preprint":false},{"pmid":"26868746","id":"PMC_26868746","title":"APR-246/PRIMA-1Met Inhibits and Reverses Squamous Metaplasia in Human Conjunctival Epithelium.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/26868746","citation_count":14,"is_preprint":false},{"pmid":"19680821","id":"PMC_19680821","title":"Expression and Localization of PRiMA-linked globular form acetylcholinesterase in vertebrate neuromuscular junctions.","date":"2009","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/19680821","citation_count":12,"is_preprint":false},{"pmid":"24804545","id":"PMC_24804545","title":"PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.","date":"2014","source":"Journal of biomedical nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24804545","citation_count":12,"is_preprint":false},{"pmid":"24982331","id":"PMC_24982331","title":"Characterizing the sphingomyelinase pathway triggered by PRIMA-1 derivatives in lung cancer cells with differing p53 status.","date":"2014","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24982331","citation_count":12,"is_preprint":false},{"pmid":"33326188","id":"PMC_33326188","title":"Co-Delivery of 131 I and Prima-1 by Self-Assembled CD44-Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics.","date":"2020","source":"Advanced healthcare materials","url":"https://pubmed.ncbi.nlm.nih.gov/33326188","citation_count":12,"is_preprint":false},{"pmid":"37101558","id":"PMC_37101558","title":"PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma.","date":"2023","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/37101558","citation_count":11,"is_preprint":false},{"pmid":"26506622","id":"PMC_26506622","title":"Dysfunctional Presynaptic M2 Receptors in the Presence of Chronically High Acetylcholine Levels: Data from the PRiMA Knockout Mouse.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26506622","citation_count":11,"is_preprint":false},{"pmid":"34689172","id":"PMC_34689172","title":"PRIMA: a rapid and cost-effective genotyping method to detect single-nucleotide differences using probe-induced heteroduplexes.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34689172","citation_count":10,"is_preprint":false},{"pmid":"23644847","id":"PMC_23644847","title":"Prima-1 induces apoptosis in bladder cancer cell lines by activating p53.","date":"2013","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/23644847","citation_count":10,"is_preprint":false},{"pmid":"27548348","id":"PMC_27548348","title":"PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc.","date":"2017","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/27548348","citation_count":10,"is_preprint":false},{"pmid":"37272907","id":"PMC_37272907","title":"In silico and in vitro investigation of dual targeting Prima-1MET as precision therapeutic against lungs cancer.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/37272907","citation_count":9,"is_preprint":false},{"pmid":"35234267","id":"PMC_35234267","title":"p53 reactivating small molecule PRIMA‑1MET/APR‑246 regulates genomic instability in MDA‑MB‑231 cells.","date":"2022","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35234267","citation_count":9,"is_preprint":false},{"pmid":"24612677","id":"PMC_24612677","title":"Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24612677","citation_count":9,"is_preprint":false},{"pmid":"19539694","id":"PMC_19539694","title":"A new variant of proline-rich membrane anchor (PRiMA) of acetylcholinesterase in chicken: expression in different muscle fiber types.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19539694","citation_count":9,"is_preprint":false},{"pmid":"18514641","id":"PMC_18514641","title":"Regulation of PRiMA-linked G(4) AChE by a cAMP-dependent signaling pathway in cultured rat pheochromocyoma PC12 cells.","date":"2008","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/18514641","citation_count":9,"is_preprint":false},{"pmid":"12882363","id":"PMC_12882363","title":"The malformation of the cerebellar fissura prima: a tool for studying histogenetic processes.","date":"2002","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12882363","citation_count":8,"is_preprint":false},{"pmid":"35164699","id":"PMC_35164699","title":"Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort.","date":"2022","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35164699","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51205,"output_tokens":3656,"usd":0.104228,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11417,"output_tokens":4231,"usd":0.08143,"stage2_stop_reason":"end_turn"},"total_usd":0.185658,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"PRiMA (proline-rich membrane anchor, encoded by PRIMA1) is the membrane anchor of acetylcholinesterase (AChE) in mammalian brain and muscle cell membranes. PRiMA organizes AChE into tetramers and anchors them at the cell surface of transfected cells; endogenous AChE in neural cell membranes is anchored through its interaction with PRiMA.\",\n      \"method\": \"Molecular cloning, transfection of COS cells, biochemical fractionation, and demonstration of AChE tetramer formation at the cell surface\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — cloning plus reconstitution in transfected cells plus demonstration in native neural membranes, foundational study replicated extensively by subsequent work\",\n      \"pmids\": [\"11804574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PRiMA is expressed predominantly in cholinergic neurons in the mouse brain, and its expression level is a limiting factor for production of the AChET–PRiMA complex (the major AChE component in brain). PRiMA exists as two alternative splice variants (PRiMA I and PRiMA II) differing in their cytoplasmic regions in both mouse and human.\",\n      \"method\": \"In situ hybridization, cholinesterase activity assays of molecular forms across brain structures, RT-PCR characterization of splice variants\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ISH, activity assays, RT-PCR) in native tissue, consistent with cloning paper\",\n      \"pmids\": [\"14622217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The proline-rich extracellular motif of PRiMA (specifically the peptidic motif RP4LP10RL) is sufficient to induce assembly of a hetero-oligomeric complex with four AChET subunits and their secretion. Short PRiMA mutants truncated within the proline-rich motif cause intracellular degradation of associated AChE subunits rather than tetramer formation.\",\n      \"method\": \"Deletion and point-mutation analysis of PRiMA expressed in transfected COS cells, measurement of secreted and membrane-bound AChE activity\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis with functional reconstitution in transfected cells, multiple mutants tested\",\n      \"pmids\": [\"17158452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PRiMA associates differently with AChE than ColQ does: in complexes formed with the PRAD of PRiMA, light (non-disulfide-linked) AChE dimers predominate, whereas heavy (disulfide-linked) dimers are rare, in contrast to ColQ-linked complexes. PRiMA has four cysteines upstream of its PRAD that can disulfide-bond all four AChE subunits.\",\n      \"method\": \"Transfection of COS cells with PRiMA/ColQ chimeras and cysteine mutants, SDS-PAGE under reducing/non-reducing conditions, analysis of native brain AChE complexes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis and chimera analysis with biochemical readout, verified in brain tissue\",\n      \"pmids\": [\"18511416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PRiMA expression in cortical neurons is transcriptionally upregulated during neuronal differentiation via a MAP kinase (Raf/MEK/ERK)-dependent signaling pathway. Inhibition of MEK with U0126 blocks both PRiMA transcript induction and PRiMA promoter-driven luciferase activity. Overexpression of activated Raf induces both PRiMA and AChET transcripts.\",\n      \"method\": \"RT-PCR, promoter-luciferase reporter assays in cortical neurons, pharmacological MEK inhibition (U0126), overexpression of active Raf mutant\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assay, pharmacological inhibition, gain-of-function) in primary neurons\",\n      \"pmids\": [\"19368807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PRiMA-linked G4 AChE is present at vertebrate neuromuscular junctions (NMJs) and is contributed by both motor neurons (spinal cord) and muscle. After denervation, expression of PRiMA, AChET, and G4 AChE decreases markedly in spinal cord and in fast- and slow-twitch muscles, indicating motor neuron–dependent regulation of this complex at the NMJ.\",\n      \"method\": \"Western blot, ELISA, immunohistochemistry in developing rat muscle and spinal cord, denervation experiments\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — denervation experiment directly links motor neuron to PRiMA/G4 AChE expression, corroborated by developmental time-course\",\n      \"pmids\": [\"19490106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PRiMA-linked AChE tetramers are localized in membrane lipid rafts of neuronal cells, and this raft association depends on a cholesterol recognition/interaction amino acid consensus (CRAC) motif at the junction of the transmembrane and cytoplasmic domains of PRiMA. The longer PRiMA I isoform confers stronger raft association than PRiMA II, implicating the cytoplasmic domain in stabilizing raft localization.\",\n      \"method\": \"Cold Triton X-100 extraction/sucrose gradient fractionation of rat brain and transfected NG108-15 cells, CRAC motif mutation analysis, developmental fractionation time-course\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — raft fractionation in native brain tissue and transfected cells, CRAC motif identified by mutagenesis, isoform comparison\",\n      \"pmids\": [\"20147288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PRiMA-linked AChE tetramers assemble from AChET and BChET homodimers (not heterodimers); dimer formation depends on catalytic domains and tetramer assembly requires the C-terminal t-peptides of cholinesterase subunits. Hybrid AChE–BChE PRiMA-linked tetramers occur naturally in chicken brain and increase during development.\",\n      \"method\": \"Co-transfection with AChET/BChET mutants and PRiMA in cultured cells, non-reducing SDS-PAGE, sucrose gradient sedimentation, Western blot of chicken brain\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — systematic mutagenesis establishes assembly rules, verified in native tissue\",\n      \"pmids\": [\"20566626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"N-linked glycosylation of AChET is required for full enzymatic activity of PRiMA-linked AChE tetramers but is not required for oligomerization. Glycan-depleted PRiMA-linked G4 AChE tetramers assemble in the endoplasmic reticulum but are not transported to the Golgi or plasma membrane.\",\n      \"method\": \"Site-directed mutagenesis of all N-glycosylation sites in AChET expressed with PRiMA in HEK293T cells, kinetic analysis (Km), subcellular fractionation, immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with glycosylation-null mutant, multiple functional and trafficking readouts\",\n      \"pmids\": [\"21795704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Presenilin-1 (PS1)/γ-secretase cleaves PRiMA, generating a C-terminal PRiMA fragment that is detectable in the nucleus. Inhibition of γ-secretase increases the level of PRiMA-linked AChE at the cell surface. The proportion of raft-residing AChE–PRiMA is altered in a PS1 conditional knockout mouse.\",\n      \"method\": \"γ-secretase inhibitor (DAPT) treatment of CHO cells overexpressing PRiMA and AChE, immunofluorescence detection of C-terminal PRiMA fragment, analysis of PS1 conditional KO mouse raft fractions\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition plus KO mouse, single lab, cleavage fragment identified but full characterization limited\",\n      \"pmids\": [\"24612677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"cAMP-dependent signaling (stimulated by dibutyryl-cAMP and forskolin) upregulates both AChET and PRiMA I mRNA expression in PC12 cells and increases G1 and G4 AChE isoforms, indicating that PRiMA-linked G4 AChE assembly is regulated by a cAMP-dependent pathway.\",\n      \"method\": \"Pharmacological treatment of PC12 cells with Bt2-cAMP/forskolin, RT-PCR, AChE activity measurement, sucrose density gradient sedimentation\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical readouts in a cell culture model, single lab\",\n      \"pmids\": [\"18514641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A homozygous splice-site mutation (c.93+2T>C) in PRIMA1 causes skipping of the first coding exon (demonstrated by minigene assay), effectively creating a PRIMA1 knockout, and segregates with autosomal recessive nocturnal frontal lobe epilepsy and intellectual disability in a human family. Consistent with PRiMA knockout mouse data showing AChE reduction and acetylcholine accumulation, loss of PRIMA1 leads to enhanced cholinergic tone as the likely disease mechanism.\",\n      \"method\": \"Whole-exome sequencing, linkage analysis, minigene splicing assay to demonstrate exon skipping, reference to PRiMA KO mouse phenotype\",\n      \"journal\": \"Annals of clinical and translational neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene functional validation of splice defect plus human genetics; disease mechanism inferred from KO mouse data\",\n      \"pmids\": [\"26339676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In PRiMA knockout mice, which develop severely reduced AChE activity and chronically elevated extracellular acetylcholine, muscarinic M2 autoreceptors are dysfunctional and fail to reduce ACh release in vivo, likely due to receptor downregulation and/or loss of receptor-effector coupling caused by chronic high ACh.\",\n      \"method\": \"PRiMA KO mouse model, in vivo microdialysis of striatal and hippocampal ACh, pharmacological challenge with oxotremorine (M2 agonist) and scopolamine (antagonist)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with in vivo functional assay, single lab\",\n      \"pmids\": [\"26506622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A second splice variant of PRiMA (PRiMA II) with a distinct 26-amino-acid cytoplasmic C-terminus exists in chicken. Both chicken PRiMA I and PRiMA II can organize G4 AChE formation when co-expressed with AChET in cultured cells. PRiMA I expression is higher in slow-twitch than fast-twitch chicken muscle, suggesting fiber-type-specific regulation of G4 AChE.\",\n      \"method\": \"RT-PCR, bioinformatic analysis, co-expression in cultured cells, fiber-type specific expression analysis\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution in cells confirmed, expression pattern data from single lab\",\n      \"pmids\": [\"19539694\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRIMA1 encodes PRiMA (proline-rich membrane anchor), a single-pass transmembrane protein that organizes acetylcholinesterase (AChE) catalytic subunits into tetramers and anchors them in plasma membrane lipid rafts of neurons and muscle cells via a proline-rich extracellular domain that binds the t-peptide of AChET; raft targeting requires a CRAC cholesterol-binding motif in PRiMA's transmembrane-cytoplasmic junction, glycosylation of AChET is needed for enzymatic activity but not assembly, γ-secretase/presenilin-1 cleaves PRiMA releasing a nuclear C-terminal fragment, PRiMA expression is transcriptionally induced during neuronal differentiation via a Raf/MEK/ERK MAP kinase pathway and by cAMP signaling, and loss-of-function mutations in PRIMA1 cause accumulation of synaptic acetylcholine leading to nocturnal frontal lobe epilepsy in humans.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PRIMA1 encodes PRiMA (proline-rich membrane anchor), the dedicated transmembrane scaffold that organizes acetylcholinesterase (AChE) catalytic subunits into G4 tetramers and anchors them at the cell surface of brain and muscle membranes [#0]. Assembly is driven by PRiMA's proline-rich extracellular motif (PRAD), which is sufficient to nucleate a hetero-oligomer of four cholinesterase T-subunits and direct their secretion or membrane retention; truncation within this motif instead diverts associated subunits to intracellular degradation [#2], and tetramer formation depends on the C-terminal t-peptides of the cholinesterase subunits [#7]. PRiMA-linked tetramers are targeted to membrane lipid rafts through a CRAC cholesterol-recognition motif at the transmembrane–cytoplasmic junction, with the longer PRiMA I isoform conferring stronger raft association [#6], while N-glycosylation of the AChE subunit is required for full catalytic activity and for trafficking beyond the endoplasmic reticulum but is dispensable for oligomerization [#8]. PRiMA is expressed predominantly in cholinergic neurons and is the limiting factor for assembly of the major brain AChE form [#1]; its transcription is induced during neuronal differentiation through a Raf/MEK/ERK pathway [#4] and by cAMP signaling [#10], and the complex is regulated at the neuromuscular junction in a motor-neuron-dependent manner [#5]. The complex is further controlled post-translationally by presenilin-1/γ-secretase, which cleaves PRiMA to release a nuclear-localized C-terminal fragment and modulates the surface pool of AChE [#9]. Loss-of-function mutation of PRIMA1 causes autosomal recessive nocturnal frontal lobe epilepsy with intellectual disability, with accumulation of synaptic acetylcholine and elevated cholinergic tone as the disease mechanism [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the molecular identity of the long-sought membrane anchor for brain and muscle AChE, answering how soluble catalytic subunits become surface-tethered tetramers.\",\n      \"evidence\": \"Molecular cloning and reconstitution in transfected COS cells, with confirmation in native neural membranes\",\n      \"pmids\": [\"11804574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the PRiMA–AChE complex not resolved\", \"Stoichiometric and kinetic details of assembly not defined at the time\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined the cellular distribution and rate-limiting role of PRiMA, showing its expression in cholinergic neurons controls how much of the major brain AChE form is produced, and revealed splice variant diversity.\",\n      \"evidence\": \"In situ hybridization, cholinesterase activity assays of molecular forms, and RT-PCR of splice variants in mouse and human tissue\",\n      \"pmids\": [\"14622217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional distinction between PRiMA I and II not established here\", \"Mechanism limiting complex production not detailed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped the assembly determinant to the proline-rich PRAD motif and showed it is both sufficient for tetramer formation and required to prevent degradation of unassembled subunits.\",\n      \"evidence\": \"Deletion and point mutagenesis of PRiMA in transfected COS cells with secreted/membrane AChE activity readouts\",\n      \"pmids\": [\"17158452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic details of PRAD–t-peptide interaction not resolved\", \"Quality-control machinery degrading mis-assembled subunits not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Distinguished PRiMA-based assembly from ColQ-based assembly and identified the cysteines that disulfide-link the tetramer, clarifying complex architecture.\",\n      \"evidence\": \"PRiMA/ColQ chimeras and cysteine mutants in COS cells, reducing/non-reducing SDS-PAGE, native brain analysis\",\n      \"pmids\": [\"18511416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of light- vs heavy-dimer predominance unknown\", \"No structural model of the disulfide network\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified a regulatory input controlling assembly, showing cAMP signaling coordinately upregulates PRiMA and AChE to increase G4 levels.\",\n      \"evidence\": \"Bt2-cAMP/forskolin treatment of PC12 cells with RT-PCR, activity assays, and sucrose gradients\",\n      \"pmids\": [\"18514641\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors mediating cAMP induction not identified\", \"Single cell-line model\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed PRiMA transcription is developmentally induced through Raf/MEK/ERK signaling, linking neuronal differentiation cues to cholinergic enzyme assembly.\",\n      \"evidence\": \"Promoter-luciferase reporters, MEK inhibition (U0126), and active-Raf overexpression in cortical neurons\",\n      \"pmids\": [\"19368807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter-binding transcription factors not defined\", \"Crosstalk with cAMP pathway not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated motor-neuron-dependent regulation of PRiMA-linked G4 AChE at the neuromuscular junction.\",\n      \"evidence\": \"Western blot, ELISA, immunohistochemistry, and denervation in rat muscle and spinal cord\",\n      \"pmids\": [\"19490106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Neuronal signals driving muscle PRiMA expression not identified\", \"Relative contributions of nerve vs muscle pools not quantified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Characterized the PRiMA II splice variant and showed both isoforms support G4 assembly, with isoform expression tracking muscle fiber type.\",\n      \"evidence\": \"RT-PCR, bioinformatics, co-expression in cultured cells, and fiber-type analysis in chicken\",\n      \"pmids\": [\"19539694\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional advantage of isoform-specific cytoplasmic tails unclear\", \"Data from chicken; mammalian relevance partial\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the lipid-raft targeting mechanism, localizing PRiMA-linked tetramers to rafts via a CRAC cholesterol-binding motif and the cytoplasmic domain.\",\n      \"evidence\": \"Detergent-resistant membrane fractionation of brain and NG108-15 cells with CRAC motif mutagenesis and isoform comparison\",\n      \"pmids\": [\"20147288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of raft residence for cholinergic signaling not established\", \"Direct cholesterol binding not biophysically measured\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established subunit assembly rules, showing tetramers build from cholinesterase homodimers via catalytic domains and t-peptides, and that natural AChE–BChE hybrids form.\",\n      \"evidence\": \"Co-transfection of AChET/BChET mutants with PRiMA, non-reducing SDS-PAGE, sedimentation, and chicken brain analysis\",\n      \"pmids\": [\"20566626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological role of hybrid tetramers unknown\", \"Determinants of homo- vs heterodimer preference not fully defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Separated the requirements for catalytic activity and assembly/trafficking, showing AChE N-glycosylation is needed for activity and ER exit but not for oligomerization.\",\n      \"evidence\": \"Glycosylation-null AChET mutants co-expressed with PRiMA in HEK293T cells with kinetic, fractionation, and immunofluorescence readouts\",\n      \"pmids\": [\"21795704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Glycan-dependent ER export checkpoint not mechanistically identified\", \"Whether PRiMA itself is glycosylation-dependent not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified post-translational proteolytic regulation, showing γ-secretase/PS1 cleaves PRiMA to release a nuclear C-terminal fragment and controls the surface AChE pool.\",\n      \"evidence\": \"DAPT treatment of CHO cells, immunofluorescence of the C-terminal fragment, and PS1 conditional KO raft analysis\",\n      \"pmids\": [\"24612677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Function of the nuclear PRiMA fragment unknown\", \"Cleavage site and physiological trigger not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected PRIMA1 loss of function to human disease, establishing it as a cause of autosomal recessive nocturnal frontal lobe epilepsy via cholinergic excess.\",\n      \"evidence\": \"Whole-exome sequencing, linkage, minigene splicing assay of a c.93+2T>C variant, referenced to KO mouse phenotype\",\n      \"pmids\": [\"26339676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Disease mechanism inferred from mouse rather than patient tissue\", \"Single family\", \"Genotype-phenotype range not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked chronic loss of PRiMA-anchored AChE to downstream cholinergic circuit dysfunction, showing M2 autoreceptor failure in vivo.\",\n      \"evidence\": \"PRiMA KO mouse with striatal/hippocampal microdialysis and muscarinic pharmacological challenge\",\n      \"pmids\": [\"26506622\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether M2 dysfunction is cause or consequence of elevated ACh not separated\", \"Receptor-level molecular changes not directly measured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The function of the γ-secretase-generated nuclear PRiMA fragment and whether PRiMA has signaling roles independent of AChE anchoring remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No identified nuclear targets or transcriptional effects of the C-terminal fragment\", \"No structural model of the PRiMA–AChE complex\", \"AChE-independent functions of PRiMA untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0112316\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [\n      \"PRiMA-AChE G4 tetramer\"\n    ],\n    \"partners\": [\n      \"ACHE\",\n      \"BCHE\",\n      \"PSEN1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}